Coxsackievirus-induced myocarditis: new trends in treatment

References

• Leonard EG. Viral myocarditis. Pediatr. Infect. Dis. J. 23, 665–666 (2004).
   PubMed Web of Science ®Google Scholar
• D’Ambrosio A, Patti G, Manzoli A et al. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart 85, 499–504 (2001).
   PubMed Web of Science ®Google Scholar
• Kearney MT, Cotton JM, Richardson PJ, Shah AM. Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management. Postgrad. Med. J. 77, 4–10 (2001).
   PubMed Web of Science ®Google Scholar
• Grist NR, Reid D. Epidemiology of viral infections of the heart. In: Viral Infections of the Heart. Banatvala JE (Ed.), Edward Arnold, London, UK, 23–31 (1993).
   Google Scholar
• Matsumori A. Hepatitis C virus infection and cardiomyopathies. Circ. Res. 96, 144–147 (2005).
   PubMed Web of Science ®Google Scholar
• Seong IW, Choe SC, Jeon ES. Fulminant coxsackieviral myocarditis. N. Engl. J. Med. 345, 379 (2001).
   PubMed Web of Science ®Google Scholar
• Shafren DR. Viral cell entry induced by cross-linked decay-accelerating factor. J. Virol. 72, 9407–9412 (1998).
   PubMed Web of Science ®Google Scholar
• He Y, Chipman PR, Howitt J et al. Interaction of coxsackievirus B3 with the full length coxsackievirus-adenovirus receptor. Nature Struct. Biol. 8, 874–878 (2001).
   PubMedGoogle Scholar
• Pevear DC, Tull TM, Seipel ME, Groarke JM. Activity of pleconaril against enteroviruses. Antimicrob. Agents Chemother. 43, 2109–2115 (1999).
   PubMed Web of Science ®Google Scholar
• Aradottir E, Alonso EM, Shulman ST. Severe neonatal enteroviral hepatitis treated with pleconaril. Pediatr. Infect. Dis. J. 20, 457–459 (2001).
   PubMed Web of Science ®Google Scholar
• Rotbart HA, Webster AD. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin. Infect. Dis. 32, 228–235 (2001).
   PubMed Web of Science ®Google Scholar
• Yanagawa B, Spiller OB, Choy J et al. Coxsackievirus B3-associated myocardial pathology and viral load reduced by recombinant soluble human decay-accelerating factor in mice. Lab. Invest. 83, 75–85 (2003).
   PubMed Web of Science ®Google Scholar
• Yanagawa B, Spiller OB, Proctor DG et al. Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus B3-mediated pancreatitis and myocarditis in mice. J. Infect. Dis. 189, 1431–1439 (2004).
   PubMed Web of Science ®Google Scholar
• Badger J, Minor I, Kremer MJ et al. Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc. Natl Acad. Sci. USA 85, 3304–3308 (1988).
   PubMed Web of Science ®Google Scholar
• Woods MG, Diana GD, Rogge MC et al. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrob. Agents Chemother. 33, 2069–2074 (1989).
   PubMed Web of Science ®Google Scholar
• Fohlman J, Pauksen K, Hyypia T et al. Antiviral treatment with WIN 54954 reduces mortality in murine coxsackievirus B3 myocarditis. Circulation 94, 2254–2259 (1996).
   PubMedGoogle Scholar
• Chern JH, Shia KS, Hsu TA et al. Design, synthesis, and structure–activity relationships of pyrazolo[3,4 d]pyrimidines: a novel class of potent enterovirus inhibitors. Bioorg. Med. Chem. Lett. 14, 2519–2525 (2004).
   PubMed Web of Science ®Google Scholar
• Crooke ST. Progress in antisense technology. Ann. Rev. Med. 55, 61–95 (2004).
   PubMed Web of Science ®Google Scholar
• Kurreck J, Wyszko E, Gillen C, Erdmann VA. Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res. 30, 1911–1918 (2002).
   PubMed Web of Science ®Google Scholar
• Mizuta T, Fujiwara M, Hatta T et al. Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A. Nature Biotechnol. 17, 583–587 (1999).
   PubMed Web of Science ®Google Scholar
• Lisziewicz J, Sun D, Klotman M et al. Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment. Proc. Natl Acad. Sci. USA 89, 11209–11213 (1992).
   PubMed Web of Science ®Google Scholar
• Marwick C. First ‘antisense’ drug will treat CMV retinitis. J. Am. Med. Assoc. 280, 871 (1998).
   PubMed Web of Science ®Google Scholar
• Filmore D. An NDA withdrawal signals another setback, but hope remains for next-generation drugs. Mod. Drug Discov. 6, 49–50 (2004).
   Google Scholar
• Opalinska JB, Gewirtz AM. Nucleic-acid therapeutics: basic principles and recent applications. Nature Rev. Drug Discov. 1, 503–514 (2002).
   PubMed Web of Science ®Google Scholar
• Yang D, Wilson JE, Anderson DR et al. In vitro mutational and inhibitory analysis of the cis-acting translational elements within the 5´ untranslated region of coxsackievirus B3: potential targets for antiviral action of antisense oligomers. Virology 228, 63–73 (1997).
   PubMed Web of Science ®Google Scholar
• Liu Z, Carthy CM, Cheung P et al. Structural and functional analysis of the 5´ untranslated region of coxsackievirus B3 RNA: in vivo translational and infectivity studies of full-length mutants. Virology 265, 206–217 (1999).
   PubMed Web of Science ®Google Scholar
• Cheung P, Zhang M, Yuan J et al. Specific interactions of HeLa cell proteins with coxsackievirus B3 RNA: La autoantigen binds differentially to multiple sites within the 5' untranslated region. Virus Res. 90, 23–36 (2002).
   PubMed Web of Science ®Google Scholar
• Yuan J, Cheung PK, Zhang H et al. A phosphorothioate antisense oligodeoxynucleotide specifically inhibits coxsackievirus B3 replication in cardiomyocytes and mouse hearts. Lab. Invest. 84, 703–714 (2004).
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Harborth J, Lendeckel W et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494–498 (2001).
   PubMed Web of Science ®Google Scholar
• Vance V, Vaucheret H. RNA silencing in plants – defense and counterdefense. Science 292, 2277–2280 (2001).
   PubMed Web of Science ®Google Scholar
• Coburn GA, Cullen BR. Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J. Virol. 76, 9225–9231 (2002).
   PubMed Web of Science ®Google Scholar
• Gil J, Esteban M. Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): mechanism of action. Apoptosis 5, 107–114 (2000).
   PubMed Web of Science ®Google Scholar
• Williams BR. Role of the double-stranded RNA-activated protein kinase (PKR) in cell regulation. Biochem. Soc. Trans. 25, 509–513 (1997).
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15, 188–200 (2001).
   PubMed Web of Science ®Google Scholar
• McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nature Rev. Genet. 3, 737–747 (2002).
   PubMed Web of Science ®Google Scholar
• Gitlin L, Karelsky S, Andino R. Short interfering RNA confers intracellular antiviral immunity in human cells. Nature 418, 430–434 (2002).
   PubMed Web of Science ®Google Scholar
• Yuan J, Cheung PK, Zhang HM, Chau D, Yang D. Inhibition of coxsackievirus B3 replication by small interfering RNAs requires perfect sequence match in the central region of the viral positive strand. J. Virol. 79, 2151–2159 (2005).
   PubMed Web of Science ®Google Scholar
• Ge Q, McManus MT, Nguyen T et al. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc. Natl Acad. Sci. USA 100, 2718–2723 (2003).
   PubMed Web of Science ®Google Scholar
• Novina CD, Murray MF, Dykxhoorn DM et al. siRNA-directed inhibition of HIV-1 infection. Nature Med. 8, 681–686 (2002).
   PubMed Web of Science ®Google Scholar
• Das AT, Brummelkamp TR, Westerhout EM et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J. Virol. 78, 2601–2605 (2004).
   PubMed Web of Science ®Google Scholar
• Ji J, Wernli M, Klimkait T, Erb P. Enhanced gene silencing by the application of multiple specific small interfering RNAs. FEBS Lett. 552, 247–252 (2003).
   PubMed Web of Science ®Google Scholar
• Holen T, Amarzguioui M, Wiiger MT, Babaie E, Prydz H. Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. Nucleic Acids Res. 30, 1757–1766 (2002).
   PubMed Web of Science ®Google Scholar
• Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nature Med. 11, 50–55 (2005).
   PubMed Web of Science ®Google Scholar
• Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation 99, 1091–1100 (1999).
   PubMed Web of Science ®Google Scholar
• Miyamoto T, Matsumori A, Hwang MW et al. Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis. J. Am. Coll. Cardiol. 37, 1713–1718 (2001).
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Schmouder RL, Slade AJ. Overview of FTY720 clinical pharmacokinetics and pharmacology. Ther. Drug Monit. 26, 585–587 (2004).
   PubMed Web of Science ®Google Scholar
• Tedesco-Silva H, Mourad G, Kahan BD et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 77, 1826–1833 (2004).
   PubMed Web of Science ®Google Scholar
• Chiba K, Yanagawa Y, Masubuchi Y et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J. Immunol. 160, 5037–5044 (1998).
   PubMed Web of Science ®Google Scholar
• Wang M, Liu S, Ouyang N et al. Protective effects of FTY720 on chronic allograft nephropathy by reducing late lymphocytic infiltration. Kidney Int. 66, 1248–1256 (2004).
   PubMed Web of Science ®Google Scholar
• Furusho K, Kamiya T, Nakano H et al. High-dose intravenous γ-globulin for Kawasaki disease. Lancet 2, 1055–1058 (1984).
   PubMed Web of Science ®Google Scholar
• Latov N, Chaudhry V, Koski CL et al. Use of intravenous γ-globulins in neuroimmunologic diseases. J. Allergy Clin. Immunol. 108, S126–S132 (2001).
   Web of Science ®Google Scholar
• Weller AH, Hall M, Huber SA. Polyclonal immunoglobulin therapy protects against cardiac damage in experimental coxsackievirus-induced myocarditis. Eur. Heart J. 13, 115–119 (1992).
   PubMed Web of Science ®Google Scholar
• Takada H, Kishimoto C, Hiraoka Y. Therapy with immunoglobulin suppresses myocarditis in a murine coxsackievirus B3 model. Antiviral and anti-inflammatory effects. Circulation 92, 1604–1611 (1995).
   PubMedGoogle Scholar
• Kishimoto C, Takamatsu N, Kawamata H, Shinohara H, Ochiai H. Immunoglobulin treatment ameliorates murine myocarditis associated with reduction of neurohumoral activity and improvement of extracellular matrix change. J. Am. Coll. Cardiol. 36, 1979–1984 (2000).
   PubMed Web of Science ®Google Scholar
• Gullestad L, Aass H, Fjeld JG et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 103, 220–225 (2001).
   PubMed Web of Science ®Google Scholar
• Drucker NA, Colan SD, Lewis AB et al. γ-globulin treatment of acute myocarditis in the pediatric population. Circulation 89, 252–257 (1994).
   PubMed Web of Science ®Google Scholar
• Kishimoto C, Shioji K, Kinoshita M et al. Treatment of acute inflammatory cardiomyopathy with intravenous immunoglobulin ameliorates left ventricular function associated with suppression of inflammatory cytokines and decreased oxidative stress. Int. J. Cardiol. 91, 173–178 (2003).
   PubMed Web of Science ®Google Scholar
• McNamara DM, Holubkov R, Starling RC et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 103, 2254–2259 (2001).
   PubMed Web of Science ®Google Scholar
• Fairweather D, Frisancho-Kiss S, Yusung SA et al. Interferon-γ protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-β 1, interleukin-1 β, and interleukin-4 in the heart. Am. J. Pathol. 165, 1883–1894 (2004).
   PubMed Web of Science ®Google Scholar
• Henke A, Zell R, Martin U, Stelzner A. Direct interferon-γ-mediated protection caused by a recombinant coxsackievirus B3. Virology 315, 335–344 (2003).
   PubMed Web of Science ®Google Scholar
• Daliento L, Calabrese F, Tona F et al. Successful treatment of enterovirus-induced myocarditis with interferon-α. J. Heart Lung Transplant. 22, 214–217 (2003).
   PubMed Web of Science ®Google Scholar
• Miric M, Vasiljevic J, Bojic M et al. Long-term follow up of patients with dilated heart muscle disease treated with human leukocytic interferon-α or thymic hormones initial results. Heart 75, 596–601 (1996).
   PubMed Web of Science ®Google Scholar
• Kuhl U, Pauschinger M, Schwimmbeck PL et al. Interferon-β treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107, 2793–2798 (2003).
   PubMed Web of Science ®Google Scholar
• Padalko E, Nuyens D, De Palma A et al. The interferon inducer ampligen [poly(I) poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis. Antimicrob. Agents Chemother. 48, 267–274 (2004).
   PubMed Web of Science ®Google Scholar
• Davis RJ. The mitogen-activated protein kinase signal transduction pathway. J. Biol. Chem. 268, 14553–14556 (1993).
   PubMed Web of Science ®Google Scholar
• Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80, 179–185 (1995).
   PubMed Web of Science ®Google Scholar
• Luo H, Yanagawa B, Zhang J et al. Coxsackievirus B3 replication is reduced by inhibition of the extracellular signal-regulated kinase (ERK) signaling pathway. J. Virol. 76, 3365–3373 (2002).
   PubMed Web of Science ®Google Scholar
• Opavsky MA, Martino T, Rabinovitch M et al. Enhanced ERK-1/2 activation in mice susceptible to coxsackievirus-induced myocarditis. J. Clin. Invest. 109, 1561–1569 (2002).
   PubMed Web of Science ®Google Scholar
• Liu P, Aitken K, Kong YY et al. The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease. Nature Med. 6, 429–434 (2000).
   PubMed Web of Science ®Google Scholar
• Pearson G, Robinson F, Beers Gibson T et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 22, 153–183 (2001).
   PubMed Web of Science ®Google Scholar
• Yasukawa H, Yajima T, Duplain H et al. The suppressor of cytokine signaling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury. J. Clin. Invest. 111, 469–478 (2003).
   PubMed Web of Science ®Google Scholar
• Jones WK, Brown M, Ren X, He S, McGuinness M. NF-κB as an integrator of diverse signaling pathways: the heart of myocardial signaling? Cardiovasc. Toxicol. 3, 229–254 (2003).
   PubMedGoogle Scholar
• Goren N, Cuenca J, Martin-Sanz P, Bosca L. Attenuation of NF-κB signalling in rat cardiomyocytes at birth restricts the induction of inflammatory genes. Cardiovasc. Res. 64, 289–297 (2004).
   PubMed Web of Science ®Google Scholar
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353, 2001–2007 (1999).
   PubMed Web of Science ®Google Scholar
• Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N. Engl. J. Med. 334, 1349–1355 (1996).
   PubMed Web of Science ®Google Scholar
• Kukin ML, Kalman J, Charney RH et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 99, 2645–2651 (1999).
   PubMed Web of Science ®Google Scholar
• Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362, 7–13 (2003).
   PubMed Web of Science ®Google Scholar
• Tschope C, Westermann D, Steendijk P et al. Hemodynamic characterization of left ventricular function in experimental coxsackieviral myocarditis: effects of carvedilol and metoprolol. Eur. J. Pharmacol. 491, 173–179 (2004).
   PubMed Web of Science ®Google Scholar
• Nishio R, Shioi T, Sasayama S, Matsumori A. Carvedilol increases the production of interleukin-12 and interferon-γ and improves the survival of mice infected with the encephalomyocarditis virus. J. Am. Coll. Cardiol. 41, 340–345 (2003).
   PubMed Web of Science ®Google Scholar
• Yuan Z, Shioji K, Kihara Y et al. Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property. Am. J. Physiol. Heart Circ. Physiol. 286, H83–H90 (2004).
   PubMed Web of Science ®Google Scholar
• Suzuki H, Matsumori A, Matoba Y et al. Enhanced expression of superoxide dismutase messenger RNA in viral myocarditis. An SH-dependent reduction of its expression and myocardial injury. J. Clin. Invest. 91, 2727–2733 (1993).
   PubMed Web of Science ®Google Scholar
• Yuan Z, Kishimoto C, Shioji K et al. Temocapril treatment ameliorates autoimmune myocarditis associated with enhanced cardiomyocyte thioredoxin expression. Mol. Cell. Biochem. 248, 185–192 (2003).
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Shioi T, Uchiyama K et al. Attenuation of virus-induced myocardial injury by inhibition of the angiotensin II type 1 receptor signal and decreased nuclear factor-κB activation in knockout mice. J. Am. Coll. Cardiol. 42, 2000–2006 (2003).
   PubMed Web of Science ®Google Scholar
• Tanaka A, Matsumori A, Wang W, Sasayama S. An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myocarditis. Circulation 90, 2051–2055 (1994).
   PubMed Web of Science ®Google Scholar
• Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 351, 1091–1093 (1998).
   PubMed Web of Science ®Google Scholar
• Saura M, Zaragoza C, McMillan A et al. An antiviral mechanism of nitric oxide: inhibition of a viral protease. Immunity 10, 21–28 (1999).
   PubMed Web of Science ®Google Scholar
• Padalko E, Ohnishi T, Matsushita K et al. Peroxynitrite inhibition of coxsackievirus infection by prevention of viral RNA entry. Proc. Natl Acad. Sci. USA 101, 11731–11736 (2004).
   PubMed Web of Science ®Google Scholar
• Zell R, Markgraf R, Schmidtke M et al. Nitric oxide donors inhibit the coxsackievirus B3 proteinases 2A and 3C in vitro, virus production in cells, and signs of myocarditis in virus-infected mice. Med. Microbiol. Immunol. (Berl). 193, 91–100 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang F, Chen Y, Yang Z et al. Cellular cardiomyoplasty for a patient with heart failure. Cardiovasc. Radiat. Med. 4, 43–46 (2003).
   PubMedGoogle Scholar
• Siminiak T, Kalawski R, Fiszer D et al. Autologous skeletal myoblast transplantation for the treatment of postinfarction myocardial injury: phase I clinical study with 12 months of follow-up. Am. Heart J. 148, 531–537 (2004).
   PubMed Web of Science ®Google Scholar
• Stamm C, Westphal B, Kleine HD et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 361, 45–46 (2003).
   PubMed Web of Science ®Google Scholar
• Chachques JC, Acar C, Herreros J et al. Cellular cardiomyoplasty: clinical application. Ann. Thorac. Surg. 77, 1121–1130 (2004).
   PubMed Web of Science ®Google Scholar
• Wang D, Coscoy L, Zylberberg M et al. Microarray-based detection and genotyping of viral pathogens. Proc. Natl Acad. Sci. USA 99, 15687–15692 (2002).
   PubMed Web of Science ®Google Scholar
• Boriskin YS, Rice PS, Stabler RA et al. DNA microarrays for virus detection in cases of central nervous system infection. J. Clin. Microbiol. 42, 5811–5818 (2004).
   PubMed Web of Science ®Google Scholar
• Striebel HM, Birch-Hirschfeld E, Egerer R, Foldes-Papp Z. Virus diagnostics on microarrays. Curr. Pharm. Biotechnol. 4, 401–415 (2003).
   PubMedGoogle Scholar
• Nikolaeva-Glomb L, Galabov AS. Synergistic drug combinations against the in vitro replication of coxsackie B1 virus. Antiviral Res. 62, 9–19 (2004).
   PubMed Web of Science ®Google Scholar